Skymark Research, who is known as a leading provider of small- and micro-cap independent investment research, has announced that they are providing complimentary trial subscriptions for Lotus Pharmaceuticals, Inc.
Best Damn Penny Stocks, a leading financial publication, is pleased to alert investors of stocks on the move. Sign Up for our Free Stock Newsletter
Lotus Pharmaceuticals, Inc. (Lotus) operates, controls and owns the pharmaceutical businesses in China of Beijing Liang Fang Pharmaceutical Co., Ltd. (Liang Fang) and Beijing En Zhe Jia Shi Pharmaceutical Co., Ltd. (En Zhe Jia), collectively Lotus East. Lotus provides business consulting and other general business operation services to Lotus East. Liang Fang is engaged in the production, trade and retailing of pharmaceuticals, focusing on the development of medicines. Liang Fang owns and operates 10 drug stores throughout Beijing, China that sell Western and traditional Chinese medications, lease medical treatment facilities to licensed physicians, and generate revenues from the leasing of retail space to third party vendors and the leasing of advertising locations at its retail stores. En Zhe Jia is a manufacturer for Liang Fang and maintains facilities for the production of medicines, Chinese medicine, as well as the research and production of other new medicines.
Sign up for the free Best Damn Penny Stocks newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website
About Best Damn Penny Stocks
Best Damn Penny Stocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer
